Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001218629-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2025-12-31 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | F - Tax | $772.09 | -28.6K | 214.5K | -12% | -$22.06M |
| D | 2026-01-05 | 2025-12-31 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | M - OptEx | $0.00 | +28.6K | 243.1K | +13% | $0 |
| D | 2026-01-05 | 2025-12-31 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | M - OptEx | $0.00 | -28.6K | 595.1K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | F | D | 28,570 | $772.09 | 214,523 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-31 | M | A | 28,570 | $0.00 | 243,093 | D | — | — | |
| 3 | Derivative | 2020 Performance Stock Units | 2025-12-31 | M | D | 28,570 | $0.00 | 595,077 | D | — · — to — | 28,570 Common Stock | (F1) Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |